Spruce Biosciences (NASDAQ:SPRB) & Athersys (NASDAQ:ATHX) Head to Head Analysis

Spruce Biosciences (NASDAQ:SPRB) and Athersys (NASDAQ:ATHX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Spruce Biosciences and Athersys”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-$38.97 million	($36.60)	-1.39
Athersys	$146,000.00	0.00	-$72.53 million	($2.03)	N/A

Spruce Biosciences has higher earnings, but lower revenue than Athersys. Spruce Biosciences is trading at a lower price-to-earnings ratio than Athersys, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Spruce Biosciences and Athersys, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1	2	5	0	2.50
Athersys	0	0	0	0	0.00

Spruce Biosciences presently has a consensus target price of $176.60, suggesting a potential upside of 248.32%. Given Spruce Biosciences’ stronger consensus rating and higher possible upside, equities analysts clearly believe Spruce Biosciences is more favorable than Athersys.

Institutional and Insider Ownership

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 19.4% of Athersys shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by insiders. Comparatively, 0.0% of Athersys shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Spruce Biosciences has a beta of 3.26, meaning that its stock price is 226% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, meaning that its stock price is 190% less volatile than the S&P 500.

Profitability

This table compares Spruce Biosciences and Athersys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
Athersys	N/A	N/A	-223.03%

Summary

Spruce Biosciences beats Athersys on 8 of the 12 factors compared between the two stocks.

About Spruce Biosciences

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.